



(51) International Patent Classification:

A61K 45/00 (2006.01) *A61P 25/28* (2006.01)
A61P 25/14 (2006.01) *C12N 5/22* (2006.01)
A61P 25/16 (2006.01) *G01N 33/483* (2006.01)

(21) International Application Number:

PCT/US2020/067368

(22) International Filing Date:

29 December 2020 (29.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/956,029 31 December 2019 (31.12.2019) US

(71) Applicant: **CHASE THERAPEUTICS CORPORATION** [US/US]; 1825 K Street NW, Suite 520, Washington, District of Columbia 20006 (US).


(72) Inventors: **CHASE, Thomas N.**; 1825 K Street NW, Suite 520, Washington, District of Columbia 20006 (US).
CLARENCE-SMITH, Kathleen; 1825 K Street NW, Suite 520, Washington, District of Columbia 20006 (US).

(74) Agent: **STORELLA, John R.** et al.; Storella & Witt, LLP, 2625 Alcatraz Ave. #197, Berkeley, California 94705 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: KINASES AS BIOMARKERS FOR NEURODEGENERATIVE CONDITIONS

FIG. 1



(57) Abstract: An assay for using signaling kinases alone or in combination with oligomeric forms of neurodegenerative proteins can include: a) providing a biological sample, e.g., a blood sample, from a subject; b) enriching for neuronally (e.g., central nervous system ("CNS")) derived microparticles, e.g., exosomes, from the blood sample; c) removing proteins from the surface of the isolated exosomes to produce scrubbed exosomes; d) determining, in the isolated internal contents, set of biomarkers including: (1) at least one signaling kinase and, optionally, at least one oligomeric form of a neurodegenerative protein; or (2) a plurality of different signaling kinases.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*